Brooks Laboratories Limited (NSE:BROOKS)
65.92
+0.17 (0.26%)
Nov 11, 2026, 2:37 PM IST
Brooks Laboratories Revenue
Brooks Laboratories had revenue of 202.33M INR in the quarter ending September 30, 2026, a decrease of -13.72%. This brings the company's total for the last twelve months to 795.39M, down -14.28% year-over-year. In the fiscal year ending March 31, 2026, Brooks Laboratories had annual revenue of 857.38M with 3.85% growth. That makes Brooks Laboratories the 38,107th largest company in the world by revenue and 3,446th in India.
Revenue (ttm)
795.39M
Revenue Growth
-14.28%
P/S Ratio
2.44
Revenue / Employee
2.29M
Employees
347
Market Cap
1.94B
Revenue by Segment
- Manufacturing 828.73M 96.7%
- Trading 28.66M 3.3%
Fiscal year ended Mar 31, 2026 See the full Brooks Laboratories breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 857.38M | 31.82M | 3.85% |
| Mar 31, 2025 | 825.57M | 30.71M | 3.86% |
| Mar 31, 2024 | 794.86M | 162.81M | 25.76% |
| Mar 31, 2023 | 632.05M | -279.80M | -30.69% |
| Mar 31, 2022 | 911.85M | 139.38M | 18.04% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Sigachi Industries | 4.91B |
| Valiant Laboratories | 3.76B |
| Jagsonpal Pharmaceuticals | 3.16B |
| Amanta Healthcare | 3.04B |
| Balaxi Pharmaceuticals | 2.80B |
| Bafna Pharmaceuticals | 1.43B |
| Alpa Laboratories | 1.11B |
| Vaishali Pharma | 1.08B |